Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tractMichael Frumovitz, Aung Naing, Mingxuan Xu et al.|Gynecologic Oncology|2020Cited by 72
Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Aung Naing, Jibran Ahmed et al.|Cancer|2023Cited by 17